Evidence map›Paper›PMID 29992584›Full record

Trial reportJournal of medical virology2018

Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs.

Ene-Ly Jõgeda, Radko Avi, Merit Pauskar, Eveli Kallas, Tõnis Karki, Don Des Jarlais, Anneli Uusküla, Karolin Toompere, Irja Lutsar, Kristi Huik

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of medical virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Virulence · 2022
    Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ene-Ly JõgedaDepartment of Microbiology, Institute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.ORCID 0000-0003-1054-0951
Radko AviDepartment of Microbiology, Institute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Merit PauskarDepartment of Microbiology, Institute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Eveli KallasDepartment of Microbiology, Institute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Tõnis KarkiDepartment of Microbiology, Institute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Don Des JarlaisDepartment of Environmental Medicine and Public Health, New York, NY, USA.
Anneli UuskülaInstitute of Family Medicine and Public Health, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Karolin ToompereInstitute of Family Medicine and Public Health, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Irja LutsarDepartment of Microbiology, Institute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Kristi HuikDepartment of Microbiology, Institute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.

Funding

Transdisciplinary Theoretical Svnthesis and Development CoreP30DA011041 · NIDA · NEW YORK UNIVERSITY · PI Holly Hagan · 1998 to 2026
$38.9M
Risk Factors for HIV/AIDS in Drug UsersR01DA003574 · NIDA · NEW YORK UNIVERSITY · PI DES JARLAIS, DON C, MCKNIGHT, COURTNEY · 1986 to 2025
$16.2M
Combined prevention to reduce initiation into injecting drug useDP1DA039542 · NIDA · NEW YORK UNIVERSITY · PI DES JARLAIS, DON C · 2015 to 2019
$4.1M
CLONING OF TUMOR ANTIGENS RECOGNIZED BY CYTOTOXIC T CELLK08CA001580 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PLAUTZ, GREGORY E · 1992 to 1995
–
NIDA NIH HHS DP1 DA039542NIDA NIH HHS R01 DA003574
6 · The paper itself

Abstract

We investigated the presence of a single-nucleotide polymorphism designated rs12979860 in the interferon λ4 (IFNλ4) gene among 345 people who inject drugs (PWID) and 495 blood donors to evaluate associations between the rs12979860 genotypes and human immunodeficiency virus/hepatitis C virus (HIV/HCV). The rs12979860 TT genotype was over-represented among HIV+ PWID than HIV- PWID and blood donors (16% vs 8% and 10%, P = 0.03, respectively). PWID with TT genotype had approximately twice the probability of being HIV+ (odds ratio [OR], 2.19; 95% confidence interval [CI], 1.11 to 4.33) than PWID without TT. Every additional year of intravenous drug use (IVDU) decreased the OR 1.16 times (OR, 0.86; 95% CI, 0.75 to 0.98). This suggests that rs12979860 TT increases susceptibility to HIV and this impact decreases with increasing duration of IVDU.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideAdultBlood DonorsCross-Sectional StudiesFemaleGenotypeHepatitis CHIV InfectionsHumansInterferon LambdaInterleukinsMaleSubstance Abuse, IntravenousIFNL4 protein, humanInterferon LambdaInterleukinsHepatitis C Virushuman immune deficiency virus/hepatitis C virus coinfectionHuman Immunodeficiency VirusInterferonsinterferon λinterleukin-28BIVDU

Identifiers

PMID29992584
PMCPMC6158102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.